Cargando…

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Switzer, Benjamin, Haanen, John, Lorigan, Paul C, Puzanov, Igor, Turajlic, Samra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288220/ https://www.ncbi.nlm.nih.gov/pubmed/34272309 http://dx.doi.org/10.1136/jitc-2021-002835

Ejemplares similares

Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection
por: Flynn, Michael, et al.
Publicado: (2018)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
por: Favara, David M, et al.
Publicado: (2020)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response
por: Stefanovic, Filip, et al.
Publicado: (2022)

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: O’Reilly, Aine, et al.
Publicado: (2019)

Questions asked in the everyday practice: immune checkpoint inhibitors
por: Haanen, John B A G
Publicado: (2018)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

New survival standards for advanced melanoma
por: Spain, Lavinia, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma
por: Wang, Qiyu, et al.
Publicado: (2022)

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
por: Alexander, James L, et al.
Publicado: (2022)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis
por: Righini, Matteo, et al.
Publicado: (2022)

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2018)

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors
por: Samnani, Sunil, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Martin, Spencer D., et al.
Publicado: (2023)

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
por: Puzanov, Igor
Publicado: (2015)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors
por: Kelly, Deirdre, et al.
Publicado: (2021)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
por: Agrawal, Nikhil, et al.
Publicado: (2019)

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2021)

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
por: Puzanov, Igor, et al.
Publicado: (2021)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer
por: Ding, Yi, et al.
Publicado: (2022)

Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors
por: Wang, Hai-Yun, et al.
Publicado: (2023)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
por: Moshirfar, Majid, et al.
Publicado: (2022)

Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy
por: Crosby, Brendan J., et al.
Publicado: (2023)

Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab
por: Hock, Barry D., et al.
Publicado: (2023)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
por: Mandala, Mario, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ucbeu5b81ronrd7gt49d1033n6